FDA staff raised concern about the design and analysis of two clinical trials of aztreonam lysine, Gilead Sciences' inhaled treatment for cystic fibrosis. Flaws in the patient questionnaire and inconsistency in the number of patients might have skewed data in favor of the drug, staff members said. Aztreonam lysine will be reviewed for approval by an advisory panel Thursday.

Related Summaries